Duijm Lucien E M, Groenewoud Johanna H, Roumen Rudi M H, de Koning Harry J, Plaisier Menno L, Fracheboud Jacques
Department of Radiology, Catharina Hospital, PO Box 1350, 5602 ZA, Eindhoven, The Netherlands.
Breast Cancer Res Treat. 2007 Nov;106(1):113-9. doi: 10.1007/s10549-006-9468-5. Epub 2007 Jan 12.
In a prospective, multi-institutional follow-up study we describe the trends in the preoperative pathologic confirmation of breast cancer of women who underwent breast cancer screening between 1995 and 2005.
We included all women aged 50-75 years who underwent biennial screening mammography in the southern breast cancer screening region of the Netherlands between February 13, 1995 and December 22, 2004. Clinical data, breast imaging reports, biopsy results and breast surgery reports were collected of all women with a positive screening result. Follow-up lasted through the next biennial screening examination and was approximately two years for all referred women.
Of 258,900 mammographic screening examinations, 3,064 (1.2%) were positive screens. The majority of women (92%) were analyzed in four regional hospitals and workup yielded breast cancer in 1,332 women. From 1995 to 2005, the percentage of breast cancer cases that underwent percutaneous biopsy prior to surgery, increased from 42.4 to 100%. The proportion of cancers with a preoperative diagnosis of malignancy by percutaneous biopsy, increased from 27.1% in 1995 to 92.7% in 2004. Preoperative breast cancer confirmation by fine needle aspiration cytology (FNAC) gradually decreased from 91.3% to 14.5%, whereas preoperative confirmation by ultrasound guided core biopsy (USCB) or stereotactic core needle biopsy (SCNB) increased from 8.7% to 69.1% and from 0 to 17.4% respectively.
A preoperative diagnosis of breast cancer is currently obtained in more than 90% of breast cancer patients. The increase in preoperative breast cancer diagnosis through 1995-2004 is correlated with the introduction of SNCB and increased use of USCB at the expense of FNAC.
在一项前瞻性、多机构随访研究中,我们描述了1995年至2005年间接受乳腺癌筛查的女性乳腺癌术前病理确诊情况的趋势。
我们纳入了1995年2月13日至2004年12月22日期间在荷兰南部乳腺癌筛查地区每两年接受一次乳腺钼靶筛查的所有50至75岁女性。收集了所有筛查结果呈阳性女性的临床数据、乳腺影像报告、活检结果和乳腺手术报告。随访持续到下一次两年一次的筛查检查,所有转诊女性的随访时间约为两年。
在258,900次乳腺钼靶筛查检查中,3,064次(1.2%)筛查结果呈阳性。大多数女性(92%)在四家地区医院接受分析,检查后1,332名女性被诊断为乳腺癌。从1995年到2005年,术前接受经皮活检的乳腺癌病例百分比从42.4%增加到100%。经皮活检术前诊断为恶性肿瘤的癌症比例从1995年的27.1%增加到2004年的92.7%。细针穿刺细胞学检查(FNAC)术前乳腺癌确诊率从91.3%逐渐降至14.5%,而超声引导下粗针活检(USCB)或立体定向粗针活检(SCNB)术前确诊率分别从8.7%增加到69.1%和从0增加到17.4%。
目前超过90%的乳腺癌患者可获得术前乳腺癌诊断。1995年至2004年期间术前乳腺癌诊断的增加与SCNB的引入以及USCB使用增加而FNAC使用减少有关。